Wegovy Pill – Oral Semaglutide

Wegovy® (semaglutide tablets) is an oral GLP-1 receptor agonist authorised in the UK for weight management in eligible adults. Unlike the traditional Wegovy injection, the tablet formulation is taken once daily.

Semaglutide works by mimicking the action of GLP-1, a naturally occurring hormone involved in appetite regulation. It can help people feel fuller for longer and may reduce food intake when used alongside a reduced-calorie diet and increased physical activity.

What Is the Wegovy Pill?

The Wegovy pill contains semaglutide, a GLP-1 receptor agonist used as part of a comprehensive weight-management programme.

The MHRA approved oral semaglutide (Wegovy) for weight loss and weight management in the UK in June 2026. It is intended for eligible adults with obesity, or adults who are overweight and have at least one weight-related health condition.

Wegovy tablets are a prescription medicine and should only be used following an assessment and prescription from an appropriately qualified healthcare professional.

How Does Oral Semaglutide Work?

Semaglutide acts on GLP-1 receptors in the body. GLP-1 is involved in appetite and feelings of fullness after eating.

As part of a weight-management programme, semaglutide may:

• Help reduce appetite
• Increase feelings of fullness
• Support reduced food intake
• Help with long-term weight management when combined with diet and physical activity

Individual results vary, and Wegovy is not intended to replace healthy eating or regular physical activity.

Who May Be Prescribed Wegovy Tablets?

According to the MHRA, oral Wegovy may be prescribed alongside a reduced-calorie diet and increased physical activity for adults with:

• A BMI of 30 or above, indicating obesity; or
• A BMI between 27 and 30 with at least one weight-related health condition.

A healthcare professional should determine whether semaglutide is appropriate for an individual patient. Other medical conditions, medicines and personal circumstances may affect whether treatment is suitable.

Wegovy Pill Dosage

The authorised UK oral semaglutide regimen starts at 1.5 mg once daily. The dose is gradually increased through 4 mg, 9 mg and 25 mg, with a minimum of one month at each dose level.

Patients should follow the dosing instructions provided by their prescriber and should not change the dose themselves.

If you are already receiving Wegovy 2.4 mg once weekly by injection through private treatment, the MHRA states that eligible patients can be transitioned directly to the 25 mg tablet once daily under appropriate medical supervision.

Common Side Effects

Like other medicines containing semaglutide, Wegovy tablets can cause side effects.

Commonly reported gastrointestinal effects include:

• Nausea
• Diarrhoea
• Constipation
• Vomiting

Side effects can vary between individuals. Speak with your doctor, pharmacist or nurse if you experience concerning or persistent symptoms.

Semaglutide also has important safety information that should be discussed with a healthcare professional before treatment. The MHRA has highlighted a very rare risk of non-arteritic anterior ischaemic optic neuropathy (NAION), which can cause sudden, painless vision loss in one eye.

Wegovy Pill vs Wegovy Injection

Both formulations contain semaglutide, but they have different methods of administration.

Wegovy tablets

• Taken orally once daily
• Contain semaglutide
• Authorised in the UK for eligible adults for weight management
• Require prescription and appropriate clinical assessment

Wegovy injection

• Administered by injection
• Uses a different dosing schedule
• Has separate licensed indications and dosing instructions

Patients should not switch between formulations without speaking to their healthcare professional.

Is the Wegovy Pill Available in the UK?

Yes. The MHRA approved Wegovy semaglutide tablets for weight management in June 2026, and Novo Nordisk subsequently announced the UK launch in July 2026.

The oral medicine is available through appropriate prescribing arrangements for eligible patients. The MHRA stated that, at the time of approval, the tablet was not available through the NHS, with NHS use subject to the relevant evaluation and decision-making processes.

Important Information Before Using Wegovy

Wegovy is a prescription medicine and is not suitable for everyone. Before treatment, a healthcare professional should review your medical history, current medicines and weight-management goals.

Never purchase or use semaglutide from an unverified source. Prescription medicines should be supplied through legitimate, regulated healthcare and pharmacy channels.

Do not use someone else’s prescription medicine, and do not change your dose without medical advice.

Wegovy Pill – Frequently Asked Questions

Is Wegovy available as a tablet?

Yes. Oral Wegovy containing semaglutide was authorised by the MHRA in the UK in June 2026. It is a once-daily tablet for eligible adults requiring weight management.

Is oral Wegovy the same as semaglutide?

Wegovy tablets contain semaglutide. Semaglutide is the active ingredient and belongs to the GLP-1 receptor agonist class of medicines.

Can I buy Wegovy tablets without a prescription?

No. Wegovy is a prescription medicine. A qualified healthcare professional must determine whether treatment is appropriate.

How often is the Wegovy pill taken?

The authorised oral formulation is taken once daily, with the dose increased gradually according to the prescribing schedule.

Can I switch from Wegovy injections to tablets?

Some eligible patients receiving the 2.4 mg weekly injection may be transitioned to the 25 mg tablet once daily. This should only happen according to the licensed guidance and under appropriate medical supervision.

Does Wegovy replace diet and exercise?

No. Wegovy is intended to be used alongside a reduced-calorie diet and increased physical activity as part of a weight-management programme.

Medical Disclaimer

This page provides general information about Wegovy (semaglutide tablets) and is not a substitute for professional medical advice. Wegovy is a prescription-only medicine. Always follow the instructions provided by your prescriber and read the official Patient Information Leaflet before using the medicine.

For official medicine information, patients and healthcare professionals can use the MHRA medicines information service to access product characteristics and patient leaflets.

Website: https://ukmeds-co.uk